Drug Profile
Tofacitinib oral - Biora Therapeutics
Alternative Names: BT-600; PGN-600Latest Information Update: 01 Apr 2024
Price :
$50
*
At a glance
- Originator Progenity
- Developer Biora Therapeutics
- Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Irritable bowel syndrome therapies; Nitriles; Piperidines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Ulcerative colitis
Most Recent Events
- 26 Mar 2024 Pharmacokinetics and adverse events data from a phase I trial in Ulcerative colitis (In volunteers) released by Biora Therapeutics
- 16 Jan 2024 Biora Therapeutics plans a GLP toxicology study for Ulcerative colitis in second-half of 2024
- 08 Jan 2024 Phase-I clinical trials in Ulcerative colitis (In volunteers) in USA (PO)